This treatment seems to be very selective to the mutation-carrying cancer cells. Because TP53 mutations are common in a variety of malignancies, they serve as an immunogenic hotspot for research on neoantigens. Additionally, compared to cell-based treatments, protein-based therapies have the benefit of being “off-the-shelf,” being much simpler to create, and being far less costly. The gene discussed is TP53; the disease is cancer.